Literature DB >> 22547583

Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura.

Marie Moatti-Cohen1, Céline Garrec, Martine Wolf, Pierre Boisseau, Lionel Galicier, Elie Azoulay, Alain Stepanian, Yahsou Delmas, Eric Rondeau, Stéphane Bezieau, Paul Coppo, Agnès Veyradier.   

Abstract

Pregnancy may be complicated by a rare but life-threatening disease called thrombotic thrombocytopenic purpura (TTP). Most cases of TTP are due to an acquired autoimmune or hereditary (Upshaw-Schulman syndrome [USS]) severe deficiency of a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13). In the present study, we performed a cross-sectional analysis of the national registry of the French Reference Center for Thrombotic Microangiopathies from 2000-2010 to identify all women who were pregnant at their initial TTP presentation. Among 592 adulthood-onset TTP patients with a severe ADAMTS13 deficiency, 42 patients with a pregnancy-onset TTP were included. Surprisingly, the proportion of USS patients (n = 10 of 42 patients [24%]; confidence interval, 13%-39%) with pregnancy-onset TTP was much higher than that in adulthood-onset TTP in general (less than 5%) and was mostly related to a cluster of ADAMTS13 variants. In the present study, subsequent pregnancies in USS patients not given prophylaxis were associated with very high TTP relapse and abortion rates, whereas prophylactic plasmatherapy was beneficial for both the mother and the baby. Pregnancy-onset TTP defines a specific subgroup of patients with a strong genetic background. This study was registered at www.clinicaltrials.gov as number NCT00426686 and at the Health Authority, French Ministry of Health, as number P051064.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22547583     DOI: 10.1182/blood-2012-02-408914

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

Review 1.  TTP: long-term outcomes following recovery.

Authors:  James N George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 2.  Thrombocytopenia in pregnancy.

Authors:  Douglas B Cines; Lisa D Levine
Journal:  Blood       Date:  2017-06-21       Impact factor: 22.113

3.  Understanding organ dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Pier Mannuccio Mannucci
Journal:  Intensive Care Med       Date:  2015-01-20       Impact factor: 17.440

Review 4.  Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.

Authors:  M Saha; J K McDaniel; X L Zheng
Journal:  J Thromb Haemost       Date:  2017-07-27       Impact factor: 5.824

Review 5.  The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective.

Authors:  James N George
Journal:  Blood Adv       Date:  2018-06-26

6.  Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Paul Knöbl; Karim Kentouche; Lawrence Rice; Jerzy Windyga; Reinhard Schneppenheim; Johanna A Kremer Hovinga; Michiko Kajiwara; Yoshihiro Fujimura; Caterina Maggiore; Jennifer Doralt; Christopher Hibbard; Leah Martell; Bruce Ewenstein
Journal:  Blood       Date:  2017-09-14       Impact factor: 22.113

Review 7.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2017-08-02       Impact factor: 22.113

8.  Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases.

Authors:  Mario Ojeda-Uribe; Naji Afif; Etienne Dahan; Laetitia Sparsa; Celine Haby; Jean Sibilia; David Ternant; Marc Ardizzone
Journal:  Clin Rheumatol       Date:  2013-01-05       Impact factor: 2.980

Review 9.  Thrombocytopenia in pregnancy.

Authors:  Douglas B Cines; Lisa D Levine
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

10.  Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura.

Authors:  Yang Jiang; Jennifer J McIntosh; Jessica A Reese; Cassandra C Deford; Johanna A Kremer Hovinga; Bernhard Lämmle; Deirdra R Terrell; Sara K Vesely; Eric J Knudtson; James N George
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.